Patents by Inventor C. Conaway

C. Conaway has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating lung cancer
    Publication number: 20060241178
    Abstract: The invention is directed to methods and compositions of inhibiting lung tumorigenesis. Such method involves the administration of an isothiocyanate conjugate at the post-initiation stage of tumor growth, while avoiding the drawbacks of toxicity of the parent compounds.
    Type: Application
    Filed: December 30, 2003
    Publication date: October 26, 2006
    Applicant: ImmuneGuard LLC
    Inventors: Fung-Lung Chung, C. Conaway, Yang-Ming Yang
  • Method for inhibition or treatment of colon tumorigenesis
    Publication number: 20060167089
    Abstract: A method is provided for inhibiting the development of colon tumorigenesis in a mammal by administering to the mammal a pharmacologically effective amount of an isothiocyanate selected from the group consisting of sulforaphane and phenethyl isothiocyanate.
    Type: Application
    Filed: August 23, 2005
    Publication date: July 27, 2006
    Inventors: Fung-Lung Chung, Bandaru Reddy, C. Conaway
  • Component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase
    Patent number: 6858709
    Abstract: Rbx1, an evolutionarily conserved Cullin-interacting RING-H2 finger protein, has been discovered. Mammalian Rbx1 has been identified as a component of the CUL2-containing VHL complex. An Rbx1 homolog from S. cerevisiae has also been identified as a subunit and activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cdk inhibitor Sic1 and for the G1/S cell cycle transition in yeast, providing a link between the multiprotein VHL tumor suppressor complex and cellular ubiquitination. The Rbx1 protein acts as a cellular marker useful (1) in detecting a possible predisposition to certain carcinomas, (2) as a molecular target for treating those carcinomas therapeutically. (3) as a target for inhibition by drugs that manipulate the growth of cells, and (4) as a research tool to better understand the various complex mechanisms of cell ubiquitination, binding of certain activator proteins, fibronectin deposition and other aspects of the cellular division process.
    Type: Grant
    Filed: February 25, 2000
    Date of Patent: February 22, 2005
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Joan W. Conaway, Ronald C. Conaway, Takumi Kamura
  • ELL2, a new member of an ELL family of RNA polymerase II elongation factors
    Publication number: 20020132329
    Abstract: ELL2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ELL2 polypeptides and polynucleotides in the design of protocols for the treatment of neoplastic disorders, among others and diagnostic assays for such conditions.
    Type: Application
    Filed: December 28, 2001
    Publication date: September 19, 2002
    Applicant: Human Genome Sciences, Inc.
    Inventors: D. Roxanne Duan, Ali Shilatifard, Joan W. Conaway, Ronald C. Conaway
  • ELL2, a new member of an ELL family of RNA polymerase II elongation factors
    Patent number: 6379923
    Abstract: ELL2 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ELL2 polypeptides and polynucleotides in the design of protocols for the treatment of neoplastic disorders, among others and diagnostic assays for such conditions.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: April 30, 2002
    Assignees: Human Genome Sciences, Inc., Oklahoma Medical Research Foundation
    Inventors: D. Roxanne Duan, Ali Shilatifard, Joan W. Conaway, Ronald C. Conaway
  • Elongin A and C functional domains
    Patent number: 6084068
    Abstract: The functional domains of Elongin A having transcriptional activation activity and Elongin BC binding activity and the functional domains of Elongin C having Elongin A activation activity and Elongin A and/or Elongin C binding activity have now been identified and isolated.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: July 4, 2000
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Ronald C. Conaway, Joan W. Conaway